Epilepsy Competitive Landscape Market Pipeline Analysis

"Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018", report provides comprehensive insights about marketed and pipeline drugs across this indication. The report provides the detailed analysis of 115+ products along with 45+ companies involved. Ultragenyx Pharmaceuticals, Takeda, and Pfizer are among the developers of most promising pipeline products.

Products covered by Phase

  • Marketed Products
  • Phase III, Phase II and Phase I
  • Pre-clinical, Discovery and Unknown Phase

Overview of pipeline development activities for Epilepsy

Pipeline analysis of 115+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.


Therapeutic segmentation of products for Epilepsy

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

  • The report provides competitive pipeline landscape of Epilepsy
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Epilepsy
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Epilepsy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Epilepsy and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario Epilepsy to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Epilepsy R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of indication therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Epilepsy to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Executive Summary

Overview

Competitive Landscape

Marketed Products

Drug Description

Commercial Activities

Product Profile

Vimpat Sales

(The list Continues)

Pipeline Therapeutics

Late Stage Products

Comparative Analysis

Cannabidiol: INSYS Therapeutics

Product Description

Research and Development

Product Development Activities

(The list continues)

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I)

Comparative Analysis

Therapeutic Assessment: Phase Products

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pre-clinical, Discovery and Unknown Products

Comparative Analysis

Dormant & Discontinued Products

Comparative Analysis

Market Drivers and Barriers

Appendix

Table 1: Total Products for Epilepsy

Table 2: Late Stage Products (Phase III)

Table 3: Mid Stage Products (Phase II)

Table 4: Early Stage Products (Phase I)

Table 5: Assessment by Monotherapy Products

Table 6: Assessment by Route of Administration

Table 7: Assessment by Stage and Route of Administration

Table 8: Assessment by Molecule Type

Table 9: Assessment by Stage and Molecule Type

Table 10: Pre-clinical, Discovery and Unknown Stage Products

Table 11: Dormant & Discontinued Products

Figure 1: Pathophysiology of Epilepsy

Figure 2: Vimpat-Historical Sales (2012-2017)

Figure 3: Lyrica-Historical Sales (2012-2017)

Figure 4: Keppra-Historical Sales (2012-2017)

Figure 5: Keppra-Historical Sales (2012-2017)

Figure 6: Topamax-Historical Sales (2012-2017)

Figure 7: Lamictal-Historical Sales (2012-2017)

Figure 8: Neurontin-Historical Sales (2012-2017)

Figure 9: Zonegran-Historical Sales (2012-2017)

Figure 10: Trileptal-Historical Sales (2012-2017)

Figure 11: Zebinix-Historical Sales (2012-2017)

Figure 12: Fycompa-Historical Sales (2012-2017)

Figure 13: Total Products for Epilepsy

Figure 14: Late Stage Products (Phase III)

Figure 15: Mid Stage Products (Phase II)

Figure 16: Early Stage Products (Phase I)

Figure 17: Assessment by Monotherapy Products

Figure 18: Assessment by Route of Administration

Figure 19: Assessment by Stage and Route of Administration

Figure 20: Assessment by Molecule Type

Figure 21: Assessment by Stage and Molecule Type

Figure 22: Pre-clinical, Discovery and Unknown Stage Products

Figure 23: Dormant & Discontinued Products

Acorda Therapeutics

Actelion

Adamas Pharmaceuticals

Addex Therapeutics

Advicenne Pharma

Aeolus Pharmaceuticals

Bio-Pharm Solutions

Biscayne Neurotherapeutics

Catalyst Pharmaceuticals

Chong Kun Dang

D-Pharm

Eisai

Epygenix Therapeutics

GlaxoSmithKline

Grupo Ferrer Internacional

GW Pharmaceuticals

INSYS Therapeutics

Marinus Pharmaceuticals

Neurelis

ORPHELIA Pharma

Ovid Therapeutics

Pfizer

Promius Pharma

Proveca

PTC Therapeutics

Retrophin

Sage Therapeutics

SciFluor Life Sciences

Serina Therapeutics

SK Biopharmaceuticals

SK Chemicals

Suda

Takeda Pharmaceutical

Techfields Pharma

Trillium Therapeutics

Turing Pharmaceuticals

UCB

Ultragenyx Pharma

Upsher-Smith Laboratories

Veritas Pharma

Vertex Pharmaceuticals

Vichem Chemie

VistaGen Therapeutics

Xenon Pharmaceuticals

XERIS Pharmaceuticals

Zambon

Zogenix

Zynerba Pharmaceuticals

  • Tags:
  • Epilepsy- Competitive Landscape
  • Market and Pipeline Analysis
  • 2018

Forward to Friend

Need A Quote